HIV genotype unneeded in new treatment computer modeling

November 26, 2013

New computer models described today in the Journal of Antimicrobial Chemotherapy predict how patients whose HIV therapy is failing will respond to any new combination of drugs, without the need for an HIV genotype: a test used in wealthy countries to read the genetic code of the virus and help select drugs to which the virus is sensitive.1 In fact, the models were significantly more accurate predictors of treatment response than the genotype.

The HIV Resistance Response Database Initiative (RDI) developed these latest models specifically for use in the many settings where genotyping is unaffordable. They estimate the probability that any combination of HIV drugs will reduce the amount of virus to undetectable levels in patients whose current therapy is failing. They were trained with data from tens of thousands of patients in clinics all over the world, including for the first time, patients from Southern Africa. They were around 80% accurate, which is significantly better than the 57% accuracy achieved by genotyping.

"This study and these models are proof of principle that this could be a very helpful approach for selecting effective therapy in highly resource-constrained settings, such as Southern Africa," commented Professor Robin Wood, Head of the Desmond Tutu HIV Centre, University of Cape Town, South Africa and a co-author on the paper." As more of our patients fail first and even second line therapy, it is critical to optimise the selection from our limited range of drugs to achieve maximum suppression of the virus and this system could be very useful".

The new models are now available to be used by healthcare professionals as part of the RDI's HIV Treatment Response Prediction System (HIV-TRePS), which is freely available online at The system also enables users to enter the costs of the drugs in their clinic and so model both the cost and the effectiveness of various options. A previous pilot study using data from an HIV clinic in India indicated that the system could identify more effective and less costly combinations of drugs that those actually used in the clinic.2

"Currently, most HIV patients in resource-limited settings are treated according to WHO public health guidelines that offer very limited treatment options", explained Dr Hugo Tempelman, Clinical Director of the Ndlovu Care Group, Elandsdoorn, South Africa and co-author on the paper. "The HIV-TRePS system, incorporating these models, enables doctors to tailor the HIV treatment based on the cost and predicted effectiveness of the treatment. What is wonderful is that HIV-TRePS provides us with high predictive value at no cost."

The data required by the system for its predictions includes a measure of the amount of virus in the patient's bloodstream (the viral load), a test that is not widely used in resource-limited settings. However, the potential cost savings offered by the system are likely to cover the costs of viral load testing, many times over. Moreover, monitoring of HIV therapy is now recommended by the World Health Organisation in all settings and initiatives are underway to fund it, including the formation of the Load Zero Foundation, formed specifically with this goal.3

"We are very encouraged by the results with these models." Commented Dr Andrew Revell, Executive Director of the RDI. "They show that not having access to genotyping in resource-limited settings need not be barrier to providing individualised, optimised HIV drug therapy".

The RDI is an independent, not-for-profit international research collaboration set-up in 2002 with the mission to improve the clinical management of HIV infection through the application of bioinformatics to HIV drug resistance and treatment outcome data. Over the 10 years since its inception, the RDI has worked with many of the leading clinicians and scientists in the world to develop the world's largest database of HIV drug resistance and treatment outcome data, containing information from approximately 100,000 patients in more than 30 countries.

HIV-TRePS is an experimental system intended for research use only. The predictions of the system are not intended to replace professional medical care and attention by a qualified medical practitioner and consequently the RDI does not accept any responsibility for the selection of drugs, the patient's response to treatment or differences between the predictions and ' responses.

Explore further: Computer models predict how patients will respond to HIV drugs

More information: 1. Revell AD, Wang D, Wood R et al. An update to the HIV-TRePS system: The development of new computational models that do not require a genotype to predict HIV treatment outcomes. J Antimicrob Chemother 2013; DOI: 10.1093/jac/dkt041

2. Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JSG, Lane HC, Larder BA. Potential Impact of a Free Online HIV Treatment Response Prediction System for Reducing Virological Failures and Drug Costs after Antiretroviral Therapy Failure in a Resource-Limited Setting. BioMed Res Int 2013; DOI: 10.1155/2013/579741.

3. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. WHO; Geneva: 2013. … Qmob954k&keytype=ref

Related Stories

Computer models predict how patients will respond to HIV drugs

March 13, 2013
Results of a study published online in the Journal of Antimicrobial Chemotherapy today (Thursday), demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. ...

CD4 count is non-inferior to viral load for treatment switching in adults with HIV

August 6, 2013
For adults infected with HIV in Thailand a monitoring strategy based on CD4 count (a type of white blood cell) is non-inferior to the recommended monitoring strategy measuring the amount of HIV virus in a patient's blood, ...

Predicting treatment response more accurately

September 2, 2013
The HI virus is feared, not least, because of its great adaptability. If the virus mutates at precisely the point targeted by a drug, it is able to neutralise the attack and the treatment fails. To minimise these viral defence ...

Protease inhibitor resistance involves multiple stages of the HIV-1 life cycle

August 27, 2013
HIV-1 protease inhibitors are very effective antiviral drugs. These drugs target HIV-1 proteases, which are required for viral replication. Despite the success of protease inhibitors for suppressing HIV-1, some patients do ...

Scientists find the invisibility cloak that shields HIV-1 from the immune system

November 21, 2013
Of the two major types of HIV, only one, HIV-1, typically causes AIDS in infected people who don't receive treatment. A study published by Cell Press November 21st in the journal Immunity reveals how HIV-1 escapes detection ...

Risk of HIV treatment failure present even in those with low viral load

November 26, 2013
People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection ...

Recommended for you

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

Scientists capture first high-resolution image of key HIV protein transitional state

July 13, 2017
A new, three-dimensional snapshot of HIV demonstrates the radical structural transformations that enable the virus to recognize and infect host cells, according to a new study led by scientists at The Scripps Research Institute ...

Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017
Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the ...

Team tests best delivery mode for potential HIV vaccine

June 20, 2017
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.